^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CYP2C9 rs1057910

    i
    Other names: CYP2C9, Cytochrome P450 Family 2 Subfamily C Member 9, P450IIC9, CYP2C10, Cytochrome P450, Family 2, Subfamily C, Polypeptide 9, Cytochrome P450 PB-1, Cytochrome P450 2C9, Cytochrome P-450MP, CYPIIC9, Cytochrome P450, Subfamily IIC (Mephenytoin 4-Hydroxylase), Polypeptide 9, Cytochrome P-450 S-Mephenytoin 4-Hydroxylase, Flavoprotein-Linked Monooxygenase, (R)-Limonene 6-Monooxygenase, (S)-Limonene 6-Monooxygenase, (S)-Limonene 7-Monooxygenase, S-Mephenytoin 4-Hydroxylase, Cholesterol 25-Hydroxylase, Microsomal Monooxygenase, Xenobiotic Monooxygenase, Cytochrome P450 MP-4, Cytochrome P450 MP-8, P450-2C9, CYP2C, CPC9
    Entrez ID:
    1559
    over1year
    Frequency of pharmacogenomic variants affecting safety and efficacy of immunomodulators and biologics in a South Asian population from Sri Lanka. (PubMed, Hum Genomics)
    Sri Lankans exhibit higher frequencies in variants reducing methotrexate efficacy (SLC19A1), increasing azathioprine myelotoxicity (NUDT15), and lower frequencies in variants linked to increased azathioprine toxicity (TPMT*3B, TPMT*3C), reduced tacrolimus efficacy (CYP3A4*18), and methotrexate toxicity risk (MTHFR). Beneficial variants enhancing rituximab efficacy (FCGR3A) are more prevalent, while those reducing tacrolimus dosage (CYP3A5*6) are less common. This highlights need for targeted medication strategies to improve treatment outcomes.
    Journal • Immunomodulating
    |
    MTHFR (Methylenetetrahydrofolate Reductase) • FCGR3A (Fc Fragment Of IgG Receptor IIIa) • CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5) • ITPA (Inosine Triphosphatase) • NUDT15 (Nudix Hydrolase 15)
    |
    CYP2C9 rs1057910
    |
    Rituxan (rituximab) • methotrexate
    almost2years
    Single-nucleotide polymorphism in CYP1A1, CYP1B1, CYP2B6, CYP2C8, and CYP2C9 genes and their association with gastrointestinal cancer: A hospital-based case-control study. (PubMed, J Cancer Res Ther)
    The findings from this study supported that polymorphism of CYP2B6*5gene may be involved in the development of GI cancer. However, other SNPs of CYP1A, CYP1B, and CYP2C genes did not signify the risk for GI cancer in the studied population of rural Maharashtra.
    Journal
    |
    CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9) • CYP1A1 (Cytochrome P450 Family 1 Subfamily A Member 1) • CYP1B1 (Cytochrome P450 Family 1 Subfamily B Member 1) • CYP2B6 (Cytochrome P450 Family 2 Subfamily B Member 6)
    |
    CYP2C9 rs1057910
    2years
    Genetic polymorphisms of CYP1A, CYP1B, CYP2C and risk of cervical cancer among rural population of Maharashtra: Findings from a hospital-based case-control study. (PubMed, J Cancer Res Ther)
    The findings from this study supported that rs1056836 SNP of CYP1B1*3 increase CC development, whereas rs4244285 of CYP2C19*2 lowers the CC risk in the studied population.
    Journal
    |
    CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9) • CYP1A1 (Cytochrome P450 Family 1 Subfamily A Member 1) • CYP1B1 (Cytochrome P450 Family 1 Subfamily B Member 1)
    |
    CYP2C9 rs1057910
    2years
    Effect of Genetic Polymorphisms on the Pharmacokinetics of Gefitinib in Healthy Chinese Volunteers. (PubMed, Xenobiotica)
    For CYP2C9*3 (rs1057910), significant differences in pharmacokinetics of gefitinib were detected between carriers of AA and AC genotypes, with higher AUC AUC and C in carrier of AC genotype than in AA genotype (BH-adjusted p value <0.05). No associations were found between SNPs in CYP3A4, CYP2D6, CYP2C19, ABCB1, ABCG2 and the pharmacokinetics of gefitinib.The SNPs in CYP3A5*3 (rs776746) and CYP2C9*3 (rs1057910) were found to be associated with altered gefitinib pharmacokinetics in healthy Chinese volunteers.
    PK/PD data • Journal
    |
    EGFR (Epidermal growth factor receptor) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5)
    |
    CYP2C9 rs1057910
    |
    gefitinib